clobetasol and Lupus-Erythematosus--Systemic

clobetasol has been researched along with Lupus-Erythematosus--Systemic* in 5 studies

Trials

1 trial(s) available for clobetasol and Lupus-Erythematosus--Systemic

ArticleYear
Treatment of chronic idiopathic urticaria with topical steroids. An open trial.
    Acta dermato-venereologica, 1996, Volume: 76, Issue:1

    Twenty-three patients with chronic idiopathic urticaria and 3 patients with urticaria pigmentosa received a 2-week treatment with daily application of potent topical steroid using plastic occlusion. Seventy per cent of the chronic urticaria patients had a statistically significant, immediate response, which, however, did not last until the final evaluation after 1.5 years. Relapse occurred after on average 3 weeks, but 39% reported less severity. The 3 patients with urticaria pigmentosa remained free from attacks for 6 to 9 months, after which they gradually relapsed. Two women were diagnosed during the follow-up period to have a carcinoma of the breast, and one patient developed systemic lupus erythematosus.

    Topics: Administration, Topical; Adolescent; Adult; Anti-Inflammatory Agents; Breast Neoplasms; Chronic Disease; Clobetasol; Female; Follow-Up Studies; Glucocorticoids; Humans; Lupus Erythematosus, Systemic; Male; Middle Aged; Occlusive Dressings; Recurrence; Retrospective Studies; Single-Blind Method; Surveys and Questionnaires; Treatment Outcome; Urticaria; Urticaria Pigmentosa

1996

Other Studies

4 other study(ies) available for clobetasol and Lupus-Erythematosus--Systemic

ArticleYear
Chilblain lupus erythematosus associated with systemic and discoid lupus erythematosus.
    Rheumatology (Oxford, England), 2021, 02-01, Volume: 60, Issue:2

    Topics: Administration, Topical; Adult; Biopsy; Chilblains; Clobetasol; Cold Temperature; Female; Glucocorticoids; Humans; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Skin; Treatment Outcome

2021
Treatment of postsurgical pyoderma gangrenosum with a high-potency topical steroid.
    Ear, nose, & throat journal, 2010, Volume: 89, Issue:6

    Pyoderma gangrenosum is a rare disease characterized by chronic, nonhealing, noninfectious ulcers that can become exacerbated by trauma or manipulation, including surgical treatment. We describe the case of a 30-year-old woman who presented with a large ulcer at the site of an excisional cervical lymph node biopsy; she also had a smaller ulcer at the site of an earlier biopsy that had been previously well healed. The ulcers persisted despite local care, and the larger ulcer was exacerbated by surgical debridement. Histopathology revealed the presence of intense neutrophilic infiltrates with sterile microabscesses-a finding consistent with pyoderma gangrenosum. With 9 weeks of treatment with a high-potency topical steroid, both ulcers gradually healed.

    Topics: Administration, Topical; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Clobetasol; Female; Humans; Lupus Erythematosus, Systemic; Postoperative Complications; Pyoderma Gangrenosum; Sjogren's Syndrome; Staphylococcus aureus; Time Factors

2010
A spectrum of lupus erythematosus from verrucous to systemic, coexisting with two types of porphyria.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2007, Volume: 21, Issue:7

    Topics: Anti-Inflammatory Agents; Clobetasol; Diagnosis, Differential; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Male; Middle Aged; Mycophenolic Acid; Porphyrias

2007
Subacute lupus erythematosus-like eruption due to terbinafine: report of three cases.
    The British journal of dermatology, 2003, Volume: 148, Issue:5

    Topics: Antifungal Agents; Clobetasol; Diagnosis, Differential; Drug Eruptions; Female; Glucocorticoids; Humans; Lupus Erythematosus, Systemic; Naphthalenes; Photosensitivity Disorders; Prednisolone; Terbinafine

2003